Insulet (PODD) closed at $145.29 on November 16, 2026, down 4.7% from the previous close, on volume of 1,869,735 shares (30-day average 1,388,602).
Data as of November 16, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 13, 2026 | Calendar Butterfly Tied to Stock | 20-Nov-26145 P : 165 C|18-Dec-26150 P : 150 C +38,100 Stock | 4,000 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
Business Wire (Mon, 9-Nov 7:00 AM ET)
Market Chameleon (Wed, 4-Nov 3:30 AM ET)
Insulet Reports Third Quarter 2026 Results
Business Wire (Wed, 4-Nov 7:00 AM ET)
Insulet to Participate in the 2026 Jefferies Global Healthcare Conference in London
Business Wire (Tue, 3-Nov 7:00 AM ET)
Globe Newswire (Fri, 30-Oct 8:55 AM ET)
Insulet Announces Omnipod Discover Now Available in U.S.
Business Wire (Mon, 12-Oct 7:00 AM ET)
Globe Newswire (Thu, 1-Oct 8:26 AM ET)
Insulet to Announce Third Quarter 2026 Financial Results on November 4, 2026
Business Wire (Thu, 1-Oct 7:00 AM ET)
Business Wire (Fri, 18-Sep 7:00 AM ET)
Globe Newswire (Mon, 14-Sep 7:19 AM ET)
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.
Insulet trades on the NASDAQ stock market under the symbol PODD.
As of November 16, 2026, PODD stock price declined to $145.29 with 1,869,735 million shares trading.
PODD has a beta of -0.57, meaning it tends to be less sensitive to market movements. PODD has a correlation of 0.04 to the broad based SPY ETF.
PODD has a market cap of $10.22 billion. This is considered a Large Cap stock.
Last quarter Insulet reported $842 million in Revenue and $1.99 earnings per share. This beat revenue expectation by $9 million and exceeded earnings estimates by $.40.
In the last 3 years, PODD traded as high as $354.88 and as low as $126.40.
The top ETF exchange traded funds that PODD belongs to (by Net Assets): VTI, VOO, RSP, VB, IVV.
PODD has underperformed the market in the last year with a price return of -56.3% while the SPY ETF gained +11.2%. However, in the short term, PODD had mixed performance relative to the market. It has outperformed in the last 3 months, returning -0.8% vs -4.6% return in SPY. But in the last 2 weeks, PODD shares have been beat by the market, returning -2.9% compared to an SPY return of -2.1%.
PODD support price is $148.82 and resistance is $156.14 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PODD shares will trade within this expected range on the day.